| Literature DB >> 32952933 |
Milena Vujovic1, Kristine Fredlund Degn1, Frederikke Isa Marin1, Anna-Lisa Schaap-Johansen1, Benny Chain2, Thomas Lars Andresen1, Joseph Kaplinsky3, Paolo Marcatili1.
Abstract
There has been increasing interest in the role of T cells and their involvement in cancer, autoimmune and infectious diseases. However, the nature of T cell receptor (TCR) epitope recognition at a repertoire level is not yet fully understood. Due to technological advances a plethora of TCR sequences from a variety of disease and treatment settings has become readily available. Current efforts in TCR specificity analysis focus on identifying characteristics in immune repertoires which can explain or predict disease outcome or progression, or can be used to monitor the efficacy of disease therapy. In this context, clustering of TCRs by sequence to reflect biological similarity, and especially to reflect antigen specificity have become of paramount importance. We review the main TCR sequence clustering methods and the different similarity measures they use, and discuss their performance and possible improvement. We aim to provide guidance for non-specialists who wish to use TCR repertoire sequencing for disease tracking, patient stratification or therapy prediction, and to provide a starting point for those aiming to develop novel techniques for TCR annotation through clustering.Entities:
Keywords: Clustering; Epitope specificity; T cell receptor (TCR); T cell receptor distance; T cell receptor similarity; T cell repertoire
Year: 2020 PMID: 32952933 PMCID: PMC7473833 DOI: 10.1016/j.csbj.2020.06.041
Source DB: PubMed Journal: Comput Struct Biotechnol J ISSN: 2001-0370 Impact factor: 7.271
Fig. 1Schematic representation of MHC antigen processing and presentation adapted from cellular and immunobiological textbooks by Janeway [8] and Abbas et al. [27]. The MHC class I or II antigen presenting molecule comes into contact with CD8+ or CD4+ T cells, respectively. The binding to the T cell receptor (TCR), which induces T cell activation, is aided by the CD8 or CD4 protein, for MHC class I or II binding mechanisms, respectively. In both figures black arrows follow MHC synthesis and antigen presentation pathways. Red arrows follow antigen processing: solid - foreign-antigen direct presentation pathway; dashed - self-antigen direct presentation pathway; dotted - foreign antigen cross-presentation. A. MHC class I antigen processing and presentation. MHCI synthesis is started off by the ribosomes in the endoplasmic reticulum (ER). Additional incorporation of β2-microglobulin into the MHCI structure is aided by a transitional complex with the auxiliary protein calnexin. To protect from unsolicited interactions, the newly synthesised MHCI is complexed with calreticulin and ERp57, and subsequently to tapasin which will assist in epitope binding. Upon transporter associated with antigen processing (TAP) protein activation antigens come through into the ER and simultaneously the MHCI-tapasin-calreticulin complex releases ERp57 and widens the peptide binding cleft which allows for binding of compatible epitopes. The loaded complex is released from ER by endosome encapsulation and transported to the cell membrane to be expressed on cell surface. Foreign and self antigen processing. Some pathogens survive internalisation and continue to produce proteins in the cytosol. Alternatively, pathogens may be internalised along with their protein product. These proteins are degraded by the proteosome into peptide fragments, epitopes, and sent to the ER for peptide-MHCI assembly and presentation. Foreign epitopes are shown in orange. Self proteins follow a similar pathway of proteosomal degradation and are sent to the ER for peptide-MHC assembly and self presentation. Self epitopes are shown in blue. All nucleated cells express MHCI and follow these pathways for endogenous antigen presentation. Cross-presentation. Exogenous antigens are usually presented on MHCII expressing cells. In order to allow for MHCI presentation of exogenous antigens specialised cells process pathogens as in the MHCII pathway, but present on MHCI complexes. Several pathways might be involved in this process. The pathogen is first internalised and enzymatically degraded in the phagolysosome. The lysosome containing peptide antigens then comes into contact with synthesised MHCI molecule and form the peptide-MHCI complex. One possible pathway is that the generated antigens are transported from the lysosome, through TAP and are loaded onto the MHCI in the ER, following which they are expressed on the cell surface. Another pathway might include a vesicular loading compartment detaching from the ER, carrying the synthesised MHCI molecule, and merging with the epitope carrying lysososme. Upon merging the epitopes could load onto the MHCI and express onto the cell surface. B. MHC class II antigen processing and presentation. Pathogens are phagocytosed into the cell interior. Upon merging with a lysosome, proteases cleave the pathogen into short peptide fragments - foreign epitopes, here shown in red. The same fate befalls the cells own proteins as they undergo degradation by the autophagosome, leaving a phagosome containing short peptides - self epitopes, here shown in blue. Meanwhile, the MHCII protein is synthesised by ribosomes in the ER. Upon assembly, MHCII binds invariant chain, Ii protein. It prevents any unwanted protein binding to the MHCII complex in the ER. The Ii chaperones MHCII out of ER in an endosome. In the endosome, due to slightly acidic conditions the Ii protein degrades leaving class II associated invariant chain peptide, CLIP fragment bound in the MHCII cleft. Upon merging with a epitope containing phagosome, the MHCII comes into contact with foreign and self antigen fragments. Upon binding the peptide-MHCII complex is expressed on the cell surface where it is able to bind CD4+ T cells. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 23D model of TCR-pMHC complex rendered via PyMOL [28],PDB reference code: 2BNR. MHC (blue) presenting peptide epitope (orange) comes into contact with the TCR (α chain light gray, β chain dark gray). Complementarity determining regions CDR1 (yellow), CDR2 (green) and CDR3 (red) come into contact with the pMHC. CDR3 comes into most contact with the presented peptide, while CDR1 and CDR2 on both chains mostly interact with the MHC. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Graphical representation of attempts to encompass structural and sequence similarity in a suitable clustering distance metric that aims to capture epitope specificity. Binding of six fictional TCRs to three fictional epitopes is depicted on the upper left side. The TCRs are shown in shades of green, purple and red, while epitopes are coloured in green, orange and light purple. If primary sequences of the TCRs are known, sequence comparison can be used to create a distance matrix TCR distance matrix. The matrix could then be used to cluster individual TCRs together based on their sequence similarity, with the goal of clustering by biological similarity i.e. epitope response. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)